Bosutinib - CAS 380843-75-4
Catalog number: 380843-75-4
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
Publictions citing BOC Sciences Products
  • >> More
1.Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.
Dvortsin E1, Gout-Zwart J1, Eijssen EL1, van Brussel J1, Postma MJ1,2. PLoS One. 2016 Jan 22;11(1):e0146551. doi: 10.1371/journal.pone.0146551. eCollection 2016.
BACKGROUND: Many oncological drugs that are being used in the adjuvant setting were first submitted for reimbursement in the metastatic stage, with differences in incremental cost-effectiveness ratios (ICERs) in both settings having potential implications for reimbursement and pricing. The aim of this study is to identify a possible trend in the cost-effectiveness for the early/adjuvant and late/metastatic stages of oncological drugs through review and case study.
2.The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Pophali PA1, Patnaik MM. Cancer J. 2016 Jan-Feb;22(1):40-50. doi: 10.1097/PPO.0000000000000165.
Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60% of patients, with approximately 20% discontinuing therapy because of intolerance and approximately 20% developing drug resistance. The advent of newer TKIs, such as nilotinib, dasatinib, bosutinib, and ponatinib, has provided multiple options for patients. These agents are more potent, have unique adverse effect profiles, and are more likely to achieve relevant milestones, such as early molecular responses (3-6 months) and optimal molecular responses (12 months). The acquisition of BCR-ABL kinase domain mutations is also reportedly lower with these drugs. Thus far, none of the randomized phase III clinical trials have shown a clinically significant survival difference between frontline imatinib versus newer TKIs. Cost and safety issues with the newer TKIs, such as vascular disease with nilotinib and ponatinib and pulmonary hypertension with dasatinib, have dampened the enthusiasm of using these drugs as frontline options.
3.Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
Sang F1,2, Ding Y1, Wang J1, Sun B1, Sun J1, Geng Y1,3, Zhang Z4, Ding K4, Wu LL1,3, Liu JW1, Bai C3, Yang G1, Zhang Q1, Li LY1, Chen Y1. J Med Chem. 2016 Feb 11;59(3):1184-96. doi: 10.1021/acs.jmedchem.5b01841. Epub 2016 Jan 27.
Natural product rakicidin A induces cell death in TKI-resistant chronic myelogenous leukemia (CML) cells. Therefore, 14 rakicidin A analogues were synthesized via a highly efficient combinatorial strategy and were evaluated against CML cell lines. The conjugated diene moiety was found to be crucial for the anti-CML activity of rakicidin A, and the changes in the configuration(s) at C-2, C-3, C-14, C-15, and C-16 resulted in lower levels of anti-CML activity. The most promising compound was 4-methylester rakicidin A (1a). Compared with rakicidin A, 1a exhibited 2.8-fold greater potency against the imatinib-resistant cell line K562/G(+) and approximately 100-fold enhanced potency compared with that of imatinib. Furthermore, compound 1a demonstrated a significantly lower resistance index against Ba/F3 cells expressing BCR-ABL(T315I) than bosutinib, dasatinib, nilotinib, and ponatinib, while 1a exhibited less effect on normal hematopoietic cells.
4.Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J1, Reisman A1, Shapiro M2, Cortes JE3, Cella D4. Curr Med Res Opin. 2016 Apr 5:1-40. [Epub ahead of print]
OBJECTIVES: The tyrosine kinase inhibitor bosutinib has demonstrated activity in patients with advanced phase chronic myeloid leukemia (CML), but effects on health-related quality of life (HRQoL) remain unexplored. This study evaluated HRQoL in advanced CML patients receiving bosutinib in an ongoing phase 2 study following resistance or intolerance to prior imatinib therapy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Src Products

CAS 221243-82-9 1-NA-PP1

(CAS: 221243-82-9)

CAS 190078-50-3 N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide

N-Acetyl-O-phosphono-Tyr-Glu Dipentylami
(CAS: 190078-50-3)

N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide is a phosphopeptide ligand for the src SH2 domain. It was used in the study of potent dipeptide inhibitors of the pp6...

CAS 837422-57-8 WH-4-023

(CAS: 837422-57-8)

WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively. The lymphocyte-specific kinase (Lck) is a ...

(CAS: 268741-42-0)

AP-2216, designed to bind selectively to the Src SH2 domain by targeting a cysteine residue, has the potential to be further developed for treating osteoporosis...

CAS 221244-14-0 1-NM-PP1

(CAS: 221244-14-0)

CAS 1380088-03-8 KB SRC 4

(CAS: 1380088-03-8)

KB SRC 4 is a cell-permeable, potent and highly selective c-Src inhibitor with Kd value of 86 nM and Ki value of 44 nM, which is a key signaling kinase in cance...

CAS 867331-82-6 TG 100801

TG 100801
(CAS: 867331-82-6)

TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kin...

CAS 212391-63-4 PD 166285 dihydrochloride

PD 166285 dihydrochloride
(CAS: 212391-63-4)

PD 166285, a novel protein tyrosine kinase inhibitor of a new structural class, is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth fact...

CAS 882663-88-9 AMG-47a

(CAS: 882663-88-9)

AMG-47a is a potent inhibitor of Lck and T cell proliferation. It has anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in...

T338C Src-IN-2
(CAS: 1351927-00-8)

T338C Src-IN-2, a pyrazolopyrimidine detivative, has been found to be a c-Src T338C kinase inhibitor and could be significant for determing the effect of kinase...

(CAS: 1808287-83-3)

CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...

CAS 897016-82-9 KX2-391

(CAS: 897016-82-9)

KX2-391 is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to t...

CAS 379231-04-6 Saracatinib

(CAS: 379231-04-6)

Saracatinib, also known as AZD0530, is an orally available dual-specific inhibitor of Src and Abl with anti-invasive and anti-tumor activities. Src and Abl are...

CAS 159439-02-8 N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu

(CAS: 159439-02-8)

N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu is a phosphopeptide ligand for the src SH2 domain with IC50 value of 1 μM. It blocks src interactions with EGFR and FAK...

CGP 77675
(CAS: 234772-64-6)

CGP 77675 selectively inhibited phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50: 5-20 and 40 nM, respectively).

CAS 380843-75-4 Bosutinib

(CAS: 380843-75-4)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.

(CAS: 1415834-63-7)

CPDA, a 4-substituted 2-pyridin-2-ylamide, has potential to inhibit SHIP2 which was found to enhance insulin signaling through the Akt pathway in viro and great...

CAS 867334-05-2 TG 100572

TG 100572
(CAS: 867334-05-2)

TG 100572 is a multi-targeted kinase inhibitor that inhibits select growth factor receptor tyrosine kinases and Src familt kinases.

CAS 172889-27-9 PP2

(CAS: 172889-27-9)

CAS 529-53-3 Scutellartln

(CAS: 529-53-3)

Scutellarein is a flavonoid isolated from Scutellaria lateriflora could improve neuronal injury.

Chemical Structure

CAS 380843-75-4 Bosutinib

Quick Inquiry

Verification code

Featured Items